As a rapidly progressing field in oncology, the adoptive transfer of T cells that have been genetically modified with chimeric antigen receptors (CARs) has shown striking efficacy in the management of hematological malignancies and has been reported in a number of clinical trials. Of note, CAR T cell therapy has shown extraordinary potential, especially in relapsed/refractory patients. However, there are still challenges regarding the further development of this strategy, spanning from engineering and manufacturing issues, to limited applications, to accompanying toxicities. In this review, we will summarize the general knowledge of this novel method, including receptor composition, applications, adverse events and challenges. Additionally, we will propose several comprehensive recommendations.
基金：
Key Program of the National Natural Science Foundation (NNSF) of China [81230052, 81630006]
第一作者单位：[1]Huazhong Univ Sci & Technol, Tongji Hosp, Dept Hematol, Tongji Med Coll, Wuhan 430030, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Yang Xin,Wang Gao-xiang,Zhou Jian-feng.CAR T Cell Therapy for Hematological Malignancies[J].CURRENT MEDICAL SCIENCE.2019,39(6):874-882.doi:10.1007/s11596-019-2118-z.
APA：
Yang, Xin,Wang, Gao-xiang&Zhou, Jian-feng.(2019).CAR T Cell Therapy for Hematological Malignancies.CURRENT MEDICAL SCIENCE,39,(6)
MLA：
Yang, Xin,et al."CAR T Cell Therapy for Hematological Malignancies".CURRENT MEDICAL SCIENCE 39..6(2019):874-882
